C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

Abstract Background Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 comp...

Full description

Bibliographic Details
Main Authors: Wei Li, Ling Xu, Xiaofang Che, Haizhou Li, Ye Zhang, Na Song, Ti Wen, Kezuo Hou, Yi Yang, Lu Zhou, Xing Xin, Lu Xu, Xue Zeng, Sha Shi, Yunpeng Liu, Xiujuan Qu, Yuee Teng
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
Breast cancer
Tamoxifen
Resistance
HER2
C-Cbl
Online Access:http://link.springer.com/article/10.1186/s12885-018-4387-5

Internet

http://link.springer.com/article/10.1186/s12885-018-4387-5

Similar Items